LOBENZARIT SODIUM

Details

Stereochemistry	ACHIRAL
Molecular Formula	C14H8ClNO4.2Na
Molecular Weight	335.65
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

[Na+].[Na+].[O-]C(=O)C1=C(NC2=C(C=CC(Cl)=C2)C([O-])=O)C=CC=C1

InChI

InChIKey=QPJBONAWFAURGB-UHFFFAOYSA-L

InChI=1S/C14H10ClNO4.2Na/c15-8-5-6-10(14(19)20)12(7-8)16-11-4-2-1-3-9(11)13(17)18;;/h1-7,16H,(H,17,18)(H,19,20);;/q;2*+1/p-2

HIDE SMILES / InChI

Description
Sources: https://chugai-pharm.jp/hc/ss/pr/drug/car_fil0080/shiori/PDF/en/car_s_en.pdf
Curator's Comment: description was created based on several sources, including: https://www.ncbi.nlm.nih.gov/pubmed/9161931 | http://www.rad-ar.or.jp/siori/english/kekka.cgi?n=750

Lobenzarit is an immunomodulator and antioxidative agent, which has been used successfully in Japan for the treatment of rheumatoid arthritis. Lobenzarit is a scavenger of oxygen-free radicals such as hydroxyl radicals, superoxide, peroxyl and singlet oxygen. Side effects of this medicine are: decreased/considerably increased urinary volume, bloody urine, frequent urination.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Glutathione reductase, mitochondrial 4 Target ID: P00390 Gene ID: 2936.0 Gene Symbol: GSR Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/8748682 \| https://www.ncbi.nlm.nih.gov/pubmed/8285143	Activator 1430
Glutathione S-transferases (rat) 2 Target ID: Glutathione S-transferases (rat) Sources: https://www.ncbi.nlm.nih.gov/pubmed/8748682	Inhibitor 8297
response to oxidative stress 20 Target ID: GO:0006979 Sources: https://www.ncbi.nlm.nih.gov/pubmed/9161931	Modulator 828

Conditions

Condition	Modality	Targets	Highest Phase	Product
Chronic rheumatoid arthritis 4 Sources: https://chugai-pharm.jp/hc/ss/pr/drug/car_fil0080/shiori/PDF/en/car_s_en.pdf https://chugai-pharm.jp/hc/ss/pr/drug/car_fil0040/if/PDF/car_if.pdf	Primary		Approved 8429	CARFENIL Approved Use This medicine improves immune abnormality and reduces inflammation and swelling of joints and so on. It is usually used to treat chronic rheumatoid arthritis. Launch Date 1986

PubMed

Title	Date	PubMed
Application of a new mathematical method for the estimation of the mean surface area to calculate the percolation threshold of lobenzarit disodium [correction of dissodium] salt in controlled release matrices.	2004 Jul	15256698
Study of the critical points in lobenzarit disodium hydrophilic matrices for controlled drug delivery.	2006 May	16651752
Investigation of the influence of particle size on the excipient percolation thresholds of HPMC hydrophilic matrix tablets.	2007 Oct	17506514

Patents

Sample Use Guides

In Vivo Use Guide

2 tablets (80 mg of the active ingredient) at a time, 3 times a day, in combination with other antiphlogistic analgesic

Route of Administration: Oral

In Vitro Use Guide

The Iobenzarit at concentrations of 1, 30, 100 and 1000 uM Iobenzarit had no inhibitory effect on various rat liver microsomal P-450 activities: on the ethoxyresorufin O-dealkylation activity, on the pentoxyresorufin O-deaikylation activity or on the p-nitrophenol hydroxylation activity, when measured in liver microsomes isolated from rats induced with beta-naphthoflavone, phenobarbital and pyrazol.

Name

Type

Language

LOBENZARIT SODIUM

Official Name

English

LOBENZARIT SODIUM [USAN]

Common Name

English

LOBENZARIT DISODIUM SALT

Common Name

English

LOBENZARIT DISODIUM

Common Name

English

BENZOIC ACID, 2-((2-CARBOXYPHENYL)AMINO)-4-CHLORO-, DISODIUM SALT

Common Name

English

LOBENZARIT SODIUM [MART.]

Common Name

English

CARFENIL

Brand Name

English

LOBENZARIT SODIUM [JAN]

Common Name

English

Lobenzarit sodium [WHO-DD]

Common Name

English

DISODIUM 4-CHLORO-2,2'-IMINODIBENZOATE

Systematic Name

English

LOBENZARIT DISODIUM SALT [MI]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C257